No headlines found.
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Globe Newswire (Thu, 16-Apr 8:00 AM ET)
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Globe Newswire (Tue, 3-Mar 8:00 AM ET)
Prime Medicine to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 25-Feb 8:00 AM ET)
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Prime Medicine trades on the NASDAQ stock market under the symbol PRME.
As of April 23, 2026, PRME stock price was flat at $3.96 with 132,453 million shares trading.
PRME has a beta of 3.11, meaning it tends to be more sensitive to market movements. PRME has a correlation of 0.15 to the broad based SPY ETF.
PRME has a market cap of $714.82 million. This is considered a Small Cap stock.
Last quarter Prime Medicine reported $838,000 in Revenue and -$.24 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.01.
In the last 3 years, PRME traded as high as $17.20 and as low as $1.11.
The top ETF exchange traded funds that PRME belongs to (by Net Assets): ARKG, XBI, VTI, IWM, VXF.
PRME has outperformed the market in the last year with a price return of +134.3% while the SPY ETF gained +36.2%. However, in the short term, PRME had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.3% vs +3.4% return in SPY. But in the last 2 weeks, PRME shares have fared better than the market returning +11.9% compared to SPY +5.2%.
PRME support price is $3.76 and resistance is $4.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRME shares will trade within this expected range on the day.
